Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841077 | 1.00 | REN (0.55) | REN | |
| SCHEMBL8904314 | 1.00 | REN (0.55) | REN | |
| SCHEMBL4698268 | 1.00 | REN (0.55) | REN | |
| SCHEMBL862279 | 0.90 | REN (0.53) | REN | |
| SCHEMBL3756599 | 0.88 | REN (0.59) | REN | |
| SCHEMBL3753975 | 0.88 | REN (0.59) | REN | |
| SCHEMBL3753978 | 0.88 | REN (0.59) | REN | |
| SCHEMBL3756596 | 0.88 | REN (0.59) | REN | |
| SCHEMBL4519855 | 0.87 | REN (0.56) | REN | |
| SCHEMBL840375 | 0.87 | REN (0.56) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143416-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-7910774-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7910774-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7910774-B2 | Alternative synthesis of renin inhibitors and intermediates thereof | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| EP-1789377-B1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| EP-1978012-A1 | Alternative synthesis of renin inhibitors and intermediates thereof | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1789377-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | Novartis AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024501-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137044-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | REN, ACE, AGT | REN 1/4885 |
| US-20070208055-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | REN, ACE, AGT | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.